1-3 of 3
Jennifer B. Lucas
Close
Sort by
Journal Articles

Results of a Prospective Phase II Trial of Limited and Extended Rituximab Treatment in Nodular Lymphocyte Predominant Hodgkin’s Disease (NLPHD).

Sandra J. Horning, MD, Nancy L. Bartlett, MD, Sheila Breslin, RN, Ranjana H. Advani, MD, Richard T. Hoppe, MD, Bradley C. Ekstrand, MD, Jennifer B. Lucas, MD
Journal: Blood
Blood (2007) 110 (11): 644.
https://doi.org/10.1182/blood.V110.11.644.644
Published: 2007
Journal Articles

A Phase II Study of Xcellerated T Cells™ in Patients with Relapsed or Refractory Indolent Non-Hodgkin’s Lymphoma (NHL).

Nancy L. Bartlett, MD, John G. Gribben, MD, DSc, Ralph V. Boccia, MD, FACP, Michael S. Milder, MD, David M. Aboulafia, MD, Januario Castro, MD, Ian Flinn, MD, PhD, Brandon Hayes-Lattin, MD, Lawrence Kaplan, MD, Thomas Lin, MD, Jennifer B. Lucas, MD, David G. Maloney, MD, Peter McLaughlin, MD, Peter A. McSweeney, MD, Ann Mohrbacher, MD, Charles Redfern, MD, Ronald Steis, MD, Joe J. Stephenson, MD, Roger Strair, MD, Ronald J. Berenson, MD, Mark W. Frohlich, MD
Journal: Blood
Blood (2004) 104 (11): 4640.
https://doi.org/10.1182/blood.V104.11.4640.4640
Published: 2004
Journal Articles

Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial

Clinical Trials & Observations
Bradley C. Ekstrand, Jennifer B. Lucas, Steven M. Horwitz, Zhen Fan, Sheila Breslin, Richard T. Hoppe, Yasodha Natkunam, Nancy L. Bartlett, Sandra J. Horning
Journal: Blood
Blood (2003) 101 (11): 4285–4289.
https://doi.org/10.1182/blood-2002-08-2644
Published: 2003